

PERSONAL DATA

Name: Partha S. Nandi M.D., FACP
Office Address: 1701 E. South Blvd, Suite 300
Rochester Hills, MI 48307
Phone: (H) 586-997-1791
(O) 586-202-0600
Fax: (248) 244-9711
Email: psnandi@yahoo.com
Citizenship: USA

EDUCATION

Undergraduate

The Ohio State University. Columbus, Ohio
B.S., Chemistry
Minor: Classical Greek Civilization
Graduated Summa Cum Laude, Phi Beta Kappa.
Rank: Top 1% of class

Medical School

Wayne State University, Detroit, Michigan
M.D.
Graduated with distinction, Alpha Omega Alpha .
Most Outstanding Internal Medicine Senior Student of the Year
Rank: Top 10 % of Class

Post-Doctoral

Internship and Residency, Wayne State University
Department of Internal Medicine, Detroit Michigan.
Voted Intern of the Year.
Permanent Medical License, State of Michigan.
Diplomate, ABIM for Internal Medicine

Gastroenterology Fellowship

University of Michigan. Ann Arbor, Michigan.
Diplomate, ABIM for Gastroenterology

HONORS

Postgraduate

1. Elected Fellow, American College of Physicians.
2. American College of Gastroenterology (ACG) outstanding presentation award at ACG National Fellows Forum.
3. Glaxo/American Medical Association national leadership award winner with invitation to national leadership conference.
4. Voted intern of the year at Wayne State University, for the most outstanding first year resident.
5. American College of Physicians National Poster Finalist.
6. Wayne State University Resident Research Award, First Place.
7. Recipient of A. Ashley Rousuck Award, for most outstanding Internal Medicine student in graduating class.
8. Recipient of Distinction in Biomedical Research award, given by the Dean for outstanding scholarship and research activities at Wayne State University.

Undergraduate

1. Graduated Summa Cum Laude.
2. Phi Beta Kappa Honorary.
3. Glenna R. Joyce full tuition merit scholarship recipient.
4. Presidential outstanding leadership award
5. Presidential academic excellence award.
6. Outstanding Minority Leader of the Ohio State University.
7. Ohio State University's Homecoming King, election by faculty and students.
8. Represented Ohio State University as Rhoades and Marshall scholarship candidate.

INDEPENDENT RESEARCH ACTIVITIES

1. Three year study (1990-93) delineating the efficacy of differing treatment regimens in patients with rib fracture.
2. Studies in immunology and gastroenterology focusing on thymosin alpha 1 (1992-94)
 - analysis of thymosin-like material in rat hepatoma and hepatoma cell lines.
 - study of HPLC and ELISA methods of detection of prothymosin and thymosin alpha1.
3. Prospective multicenter study comparing Savary vs. Balloon dilation for peptic esophageal strictures (1997-2000)
 - Coordinated study at lead center, University of Michigan.

4. Prospective blinded study comparing EUS, ERCP and Magnetic Resonance Cholangiopancreatography in detection of extrahepatic biliary disease (1997-99)
 - Formulated, organized and performed research protocol.
 - Funding obtained through grant from Clinical Research Center, University of Michigan.
 - ASGE Plenary Session oral presentation, Digestive Disease Week (DDW) 1999.
 - Presented findings at North American Conference of GI Fellows and ASGE Young Investigators Meeting.
5. Retrospective study to determine the efficacy of cholecystectomy in the treatment of biliary dyskinesia (2002-2006)
 - Formulated and organized research protocol with residents at William Beaumont hospital
 - Findings presented at annual research forum at William Beaumont Hospital, Troy
 - Resident researcher winner of outstanding research award.

LEADERSHIP ACTIVITIES

1. **President**, Center for Digestive Health, Troy, MI (2007-2009)
2. Board of Directors, Michigan State Medical Society (2005-2008).
3. Blue Cross Blue Shield of Michigan Board and Physician Contract Advisory Committee (2005-present).
4. Board of Directors, Oakland County Medical Society (2001-present).
5. Alternate Delegate to American Medical Association (AMA) House of Delegates (May 2002-present).
6. American College of Physicians (ACP) Young Physician Subcommittee member (2001-2004).
7. **Co-chair** Michigan State Medical Society (MSMS) Membership committee (2002-2004).
8. American Society of Gastrointestinal Endoscopy (ASGE) Health and Public Policy Committee member (2000-2003).
9. **Chair** of American Gastroenterological Association (AGA) Young GI and Trainee Committee (1999-2002).
10. **Chair** of AMA House of Delegates Rules and Credentials Committee (June 1999).
11. **Chair** of AGA National Trainee subcommittee (1998-99).
12. AGA national Manpower and Training Committee member (1997-1999).
13. **Chair** of Michigan State Medical Society Resident's Section (1996-97).
14. Michigan delegate to AMA House of Delegates, (1997-99)
15. National Governing Council Member of American Society of Internal Medicine resident physicians section (1995-96, 1997-98).

16. Resident delegate to AMA, Resident Physicians Section (RPS). Author of eight resolutions at AMA-RPS Meetings (1994-1998).
17. Member of Michigan Society of Internal Medicine (MSIM) Board of Trustees and Michigan's resident representative to ASIM's Resident Physicians Section (1995-1998).
18. Committee member, Medical and Public Health Issues of Wayne County Medical Society (1994-1996).
19. Ethics Committee at Harper Hospital, Detroit, Michigan (1995-96)

Publications

1. Scheiman JM, Carlos RC, Barnett JL, Elta GH, Nostrant TT, Chey WD, Francis IR, **Nandi PS**. Can endoscopic ultrasound or magnetic resonance cholangiopancreatography replace ERCP in patients with suspected biliary disease? A prospective trial and cost analysis. *Am J Gastroenterol*. 2001 Oct; 96(10):2900-4.
2. **Nandi PS**, Scheiman JS. Endoscopic Management of Biliary Disease. *Current Opinion in Gastroenterology* 1997; 13: 432-438.
3. Scheiman JS, **Nandi PS**. Endoscopic Ultrasound of the Pancreas. In: *Ultrasound in Surgical Practice: Basic Principles and Clinical Applications*. New York: John Wiley and Sons. (in press)
4. Nostrant TT, **Nandi PS**. Esophageal Dilation. *The Gastroenterologist* 1998; 5-15.
5. Chandrasekhar PH, **Nandi PS**, Crane L. Extracerebral Acanthamoebiasis: A Report of Two Cases and Review of the Literature. *Archives of Internal Medicine* 1997; 157:569-572.
6. MacArthur RD, **Nandi PS**, McMillen L, Crane L. CT guided brain biopsy findings in HIV infected persons: a retrospective review of 44 cases at an urban center. *Int. Conf. AIDS* 1996; 11: 106.
7. Dombi GW, **Nandi PS**, Saxe JM, Ledgerwood AM, Lucas CE. Prediction of Rib Fracture Injury Outcome by an Artificial Neural Network. *The Journal of Trauma* 1995; 39: 915-921.
8. Naylor PH, Shafritz DA, Sasaki D, Madduri M, Smith MR, Silverman AI, **Nandi P**, Mutchnik MG., Production of thymosin alpha 1 and thymosin-like material by a Hepg2 line. *Hepatology* 1993; 18: 85A.

Presentations

1. **Nandi PS**, Barnett JL, Elta GH, Prince M, Francis I, Carlos R, Scheiman J. Accuracy of EUS and MRCP: A blinded prospective comparison with ERCP in pts with biliary disease. **Invited American Society of Gastrointestinal Endoscopy plenary session (oral presentation)**, Digestive Diseases Week, 1999. Orlando.
2. **Nandi PS**, Hasler W. Small Bowel Melanoma: a rare cause of iron deficiency anemia. American College of Gastroenterology (ACG) National Fellows Forum, June 1999. San Diego.

3. **Nandi PS**, Delvalle J. Hemolytic Uremic Syndrome and Pancreatitis associated with Pseudomonas Aeruginosa Diarrhea. ACG National Fellows Forum, August 1997. **Winner of outstanding oral presentation award.**
4. **Nandi PS**, Barnett JL, Scheiman JM. Endoscopic Ultrasound is the most cost-effective method of evaluating patients with suspected choledocholithiasis. North American Conference of GI fellows. March 1998.
5. MacArthur RD, **Nandi PS**, McMillen L, Crane L. CT Guided Brain Biopsy Findings in HIV-Infected Persons: A Retrospective Review of 44 cases at an urban medical center. Presented at the XI International Conference on AIDS, Vancouver, July 1996.
6. **Nandi PS**, Ruble C. CMV Sinusitis: The first reported case in a patient with HIV infection. American College of Physicians (ACP) National Poster Finalist, 1996.
7. **Nandi PS**, Levine D. Kaposi's Varicelliform Lesions associated with sun exposure. Presented at ACP Scientific Meeting, September 1995.
8. **Nandi PS**, Lockette W. Cardiac Amyloidosis. Presented at ACP Scientific Meeting, September 1994.

Research Projects

Multicenter, Double-Blind Study of Nitazoxanide Compared to Vancomycin in the Treatment of Clostridium Difficile-Associated Disease—**Principal Investigator**

Efficacy and Safety of Daily Infergen/Ribavirin in Patients with Chronic Hepatitis C Virus Infection Who Were Partial Responders after Peginterferon alfa/Ribavirin Therapy—**Principal Investigator**

A Phase III, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of Renzapride in Women with Constipation-Predominant Irritable Bowel Syndrome (c-IBS)

A Phase III, Multicenter, Open Label, Extension Study to Evaluate the Long-term Safety of Renzapride 4 mg Once Daily in Women with Constipation-Predominant Irritable Bowel Syndrome (c-IBS)

Multicenter, Randomized, Double-Blind, Active-Controlled Trial Comparing Remicade® (infliximab) and Remicade plus Azathioprine to Azathioprine in the Treatment of Patients with Crohn's Disease Naïve to both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naïve Patients in Crohn's Disease - SONIC)

A Study to Investigate the Effect of Two Doses of CREON® on Maldigestion in Patients with Exocrine Pancreatic Insufficiency due to Chronic Pancreatitis.

A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and

Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis.

A Phase IIIb, Multicenter, Double-Blind, Placebo-Controlled, Randomized Trial to Examine the Corticosteroid-Sparing Effect of Certolizumab Pegol in Patients with Moderate to Severe Crohn's Disease (COSPAR I)

Projects (concluded)

A Phase 3 study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg QD and 90 mg QD) Compared to Placebo on Symptom Relief in Subjects with Symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD)—**Principal Investigator**

A Phase 3, Open-Label Study to Assess the Long-term Safety of TAK-390MR (60 mg QD and 90 mg QD)—**Principal Investigator**

An Open Label 52-Week Study to Evaluate the Safety and Efficacy of Tegaserod (6mg BID and 12 mg OD) Given Orally for the Treatment of Opioid-Induced Constipation (OIC) in Patients with Chronic Non-Cancer Pain—**Principal Investigator**.

A prospective comparison of air contrast barium enema (ACBE), computed tomographic colonoscopy (virtual colonoscopy) and colonoscopy for evaluation of the colon (NIH 2003).

A multi-center, randomized, parallel-group, active-controlled double blind study conducted under in-house blinding conditions to determine the incidence of gastroduodenal ulcers in patients with osteoarthritis or rheumatoid arthritis after 12 weeks of treatment with L-001069957 21mg plus low dose aspirin, L-001069957 42mg plus low dose aspirin, celecoxib 400mg plus low dose aspirin, or low dose aspirin alone, Protocol 003.

A 6-week randomized, double-blind, double-dummy placebo-controlled, multicenter study to assess the effect of tegaserod 2 mg tid and 6 mg tid, on dyspeptic symptoms in diabetic patients with symptoms of diabetic gastropathy.

A multicenter, double-blind, randomized trial of the relationship of intragastric acid control and healing status of moderate and severe erosive esophagitis after treatment with esomeprazole magnesium (NEXIUM) 10 mg and 40 mg daily.

A 4-week, multicenter, double-blind, placebo-controlled, randomized, parallel-group, clinical study to evaluate the efficacy of tegaserod in relieving the symptoms of female patients with Irritable Bowel Syndrome (IBS), excluding those with predominant diarrhea IBS

A 6 week, randomized, double blind, placebo controlled, multi-center study, to assess the

efficacy and safety of oral tegaserod (6mg bid) and placebo in female patients with dyspepsia.

A one-year, open-label, multi-center, extension study to CHTF919D2302 to assess the long term safety of tegaserod 6 mg bid orally in female patients with symptoms of dyspepsia.

A Multicenter, Randomized, Blinded, Placebo-controlled, Phase IIa Study of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects With Crohn's Disease Inadequately Controlled by 5-Aminosalicylates and/or Corticosteroids, and Open-label Administration in Subjects Who are Nonresponders to Anti-TNF α Therapy

Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Retreatment Study of Sargramostim (Leukine®) in Patients With Active Crohn's Disease and Prior Treatment Response to Sargramostin

Open-Label Trial of Leukine® (Sargramostin), A Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), in Active Crohn's Disease

A Phase 3, Randomized, Double-Blind, Active-Controlled Study to Assess the Efficacy and Safety of Aquavan® (Fospropofol disodium) Injection for Minimal-to-Moderate Sedation in Patients Undergoing Colonoscopy

A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg QD and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis

A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects with Healed Erosive Esophagitis

A Multicenter, Open Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Patients with Moderate to Severe Crohn's Disease with Previous Exposure to Infliximab.